STOCK TITAN

Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Theratechnologies, a biopharmaceutical company, announced it will report its financial results and provide a business update for the second quarter ending May 31, 2024. The announcement will be made on July 10, 2024, at 8:30 a.m. ET. The call will be hosted by President and CEO Paul Lévesque, alongside other members of the management team including CFO Philippe Dubuc, CMO Christian Marsolais, and Global Commercial Officer John Leasure. Participants are encouraged to join the call early. Dial-in and replay information is available for interested parties.

Positive
  • Announcement of an upcoming financial results release date suggests transparency.
  • Participation of key executives in the call enhances credibility and investor confidence.
Negative
  • None.

MONTREAL, June 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its second quarter ended May 31, 2024, on Wednesday, July 10 at 8:30 a.m. ET.

The call will be hosted by Paul Lévesque, President and Chief Executive Officer. He will be joined by other members of the management team, including Philippe Dubuc, Senior Vice President and Chief Financial Officer, Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer and John Leasure, Global Commercial Officer who will be available to answer questions from participants following prepared remarks.

Participants are encouraged to join the call at least ten minutes in advance to secure access. Conference call dial-in and replay information can be found below.

CONFERENCE CALL INFORMATION
Conference Call DateJuly 10, 2024
Conference Call Time8:30 a.m. ET
Webcast linkhttps://edge.media-server.com/mmc/p/4mkgkywo
Dial in1-888-513-4119 (toll free) or 1-412-902-6615 (international)
Access Code0474907
CONFERENCE CALL REPLAY
Toll Free1-877-344-7529 (US) / 1-855-669-9658 (Canada)
International Toll1-412-317-0088
Replay Access Code4477930
Replay End DateJuly 17, 2024
To access the replay using an international dial-in number, please select this link:
https://services.choruscall.com/ccforms/replay.html
 

An archived webcast will also be available on the Company’s Investor Relations website under ‘Past Events’.

About Theratechnologies

Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and X (formerly Twitter). 

Contacts:

Investor inquiries:
Philippe Dubuc
Senior Vice President and Chief Financial Officer
pdubuc@theratech.com
438-315-6608

Media inquiries:
Julie Schneiderman
Senior Director, Communications & Corporate Affairs
communications@theratech.com
1-514-336-7800


FAQ

When will Theratechnologies announce its Q2 2024 financial results?

Theratechnologies will announce its Q2 2024 financial results on July 10, 2024, at 8:30 a.m. ET.

What is the stock symbol for Theratechnologies?

The stock symbol for Theratechnologies is THTX.

Who will host the Q2 2024 financial results call for Theratechnologies?

The call will be hosted by Paul Lévesque, President and CEO of Theratechnologies.

How can I access the replay of the Theratechnologies Q2 2024 financial results call?

You can access the replay until July 17, 2024, using toll-free or international numbers provided in the announcement, or visit the company’s Investor Relations website.

Theratechnologies Inc. Common

NASDAQ:THTX

THTX Rankings

THTX Latest News

THTX Stock Data

56.33M
45.98M
6.29%
51.21%
0.06%
Biotechnology
Healthcare
Link
United States of America
Montreal